Registration and Notification 
Shareholders who wish to participate in the meeting must: 

• be registered in the share register maintained by Euroclear Sweden AB as of Wednesday, 9 July 2025; and 
• notify their intention to attend the meeting no later than Friday, 11 July 2025 by mail to Chordate Medical Holding AB (publ), c/o Kista Science Tower, Floor 31, Färögatan 33, 164 51 Kista, Sweden (please mark the envelope “EGM Chordate”), by telephone at +46 (0)8-400 115 46, or by email to niklas.lindecrantz@chordate.com. 

Shareholders whose shares are nominee-registered through a bank or other manager must, in addition to giving notice of attendance, register their shares in their own name to be entitled to participate in the meeting. Such registration may be temporary (so-called “voting rights registration”) and must be completed by the record date on 9 July 2025. Shareholders should request that their nominee perform such registration well in advance, in accordance with the nominee’s procedures. Voting rights registrations made by the nominee no later than 11 July 2025 will be considered in the preparation of the share register. 

Proxies 
Shareholders who wish to participate via proxy must submit a written, dated proxy signed by the shareholder to the company by mail to Chordate Medical Holding AB (publ), c/o Kista Science Tower, Floor 31, Färögatan 33, 164 51 Kista, Sweden. Proxy forms are available on the company’s website, www.chordate.com. If the shareholder is a legal entity, a certificate of registration or other authorization document must be attached. 

Proposed Agenda 

1. Opening of the meeting 
2. Election of Chairman of the meeting 
3. Preparation and approval of the voting list 
4. Election of one or two persons to verify the minutes 
5. Determination of whether the meeting has been duly convened 
6. Approval of the agenda 
7. Resolution to approve the Board of Directors' decision on a directed new issue 
8. Closing of the meeting 

Proposals for Resolutions 

Item 7 – Resolution to approve the Board of Directors' decision on a directed new issue 
The Board of Directors proposes that the Extraordinary General Meeting resolve to approve the Board’s decision of 30 June 2025 on a directed new issue of not more than 637,500 preference shares, resulting in an increase of the share capital by not more than SEK 2,550,000. The resolution shall otherwise be governed by the following terms: 

1. The right to subscribe for the new shares shall accrue to Sifonen AB, Tommy Hedberg with related parties, and Caroline Brandberg with related parties. The reasons for the deviation from the shareholders’ preferential rights are the Board’s overall assessment, in which the possibility of raising capital through a rights issue has been considered. However, the Board has concluded that a rights issue at this time would entail excessive costs for the company and thus an excessive financial burden. Furthermore, a rights issue carries the risk of not being fully subscribed, meaning that the costs may further exceed what is proportionate to the expected issue proceeds. It is especially noted that in February 2025 the company announced the outcome of a rights issue which was only subscribed to just over 60 percent with preferential rights, whereby guarantee undertakings, for which the company paid compensation, had to be fulfilled. In addition, the Board assesses that a rights issue would likely have needed to be carried out at a discount to the current market price, which would not have been possible given the quota value of the share. The directed issue will be carried out at a premium to the market price, which is more favorable for the Company as well as its shareholders. The Directed Issue is expected to strengthen the company’s ability to carry out the final step of the strategic plan involving the sale of the business to an external party, which the Board considers would be advantageous for both the company and its shareholders.
2. A subscription price of SEK 4 shall be paid for each share, corresponding to the share’s par value. The subscription price represents a premium of 60 percent compared to the closing price on Nasdaq First North Growth Market on 30 June 2025 (2.50 SEK), and a premium of 7.53 percent to the volume-weighted average price (VWAP) over the last 20 trading days (SEK 3.72) prior to 30 June 2025. Since the subscription price, set at par value, is above both the closing and VWAP prices, the Board considers the price to be market-based and not granting any undue benefit to the subscribers. 
3. The share premium shall be allocated to the unrestricted share premium reserve. 
4. Subscription of the new shares shall be made within one week from the date of the meeting’s approval of the issue resolution. Payment shall be made within one week from subscription. 
5. The Board shall be entitled to extend the subscription and payment period. 
6. The new shares shall carry entitlement to dividends from the first record date for dividends following their registration with Euroclear Sweden AB. 
7. The preference shares shall be subject to redemption conditions. 
8. The Board of Directors, or the person appointed by the Board, is authorized to make minor adjustments to the resolution as may be required for registration with the Swedish Companies Registration Office (Bolagsverket). 

Since the resolution partly relates to parties covered by Chapter 16 of the Swedish Companies Act (the so-called “LEO Law”), the resolution must be supported by shareholders representing at least nine-tenths of both the votes cast and the shares represented at the meeting to be valid. 

Other Information 
The Board of Directors and the CEO shall, if any shareholder so requests and the Board deems it possible without significant harm to the company, provide information regarding circumstances that may affect the assessment of any matter on the agenda. 

Documents pursuant to Chapter 13, Section 6 of the Swedish Companies Act will be available on the company’s website, www.chordate.com, no later than two weeks prior to the meeting and will be sent to shareholders who request them and provide their address. 

For processing of personal data, please refer to the privacy policy available via the following link: 
https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf 
_____________________ 
Chordate Medical Holding AB (publ) 
the board of directors 

Registration and notification
Shareholders who wish to participate at the general meeting must

• be recorded in the share register kept by Euroclear Sweden AB on Tuesday 13 May 2025, and
• give notice of their intention to participate at the general meeting no later than Thursday 15 May 2025 by post to Chordate Medical Holding AB (publ), Kista Science Tower, floor 31, Färögatan 33, 164 51 Kista, Sweden (please mark the envelope ”AGM Chordate”), by telephone to 08-400 115 46 or by e-mail to niklas.lindecrantz@chordate.com.

For shareholders who have their shares registered through a bank or other nominee, the following applies in order to be entitled to participate in the general meeting. In addition to giving notice of participation to the general meeting, such shareholder must re-register its shares in its own name so that the shareholder is registered in the share register kept by Euroclear Sweden AB as of the record date on 13 May 2025. Such registration may be temporary (so-called voting rights registration). Shareholders who wish to register their shares in their own names must, in accordance with the respective nominee´s routines, request that the nominee makes such registration. Voting rights registration that have been requested by the shareholder at such time that the registration has been completed by the nominee no later than on 15 May 2025, will be taken into account in the preparation of the share register.

Power of attorney
If a shareholder wishes to attend the general meeting by proxy, a written and dated power of attorney signed by the shareholder in original copy must be sent by post to Chordate Medical Holding AB (publ), Kista Science Tower, floor 31, Färögatan 33, 164 51 Kista, Sweden. A proxy form is available on the company's website www.chordate.com. If the shareholder is a legal person, a certificate of registration or other authorization document must be attached to the form.

Agenda for the general meeting

1. Opening of the general meeting
2. Election of chairman at the general meeting
3. Preparation and approval of the voting list
4. Election of one or two persons who shall approve the minutes of the general meeting
5. Determination of whether the meeting has been duly convened
6. Approval of the agenda
7. Presentation of the annual report and the auditor’s report as well as the consolidated financial statement and the auditor’s report for the group as well as presentation by the chairman of the board of directors and by the CEO
8. Resolution on
   a. the adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet
   b. the dispositions in respect of the company’s profit and loss pursuant to the adopted balance sheet
   c. discharge from liability of the directors and the CEO
9. Determination of the number of directors, deputy directors, auditors and deputy auditors
10. Determination of the fees to the board of directors and the auditor
11. Election of the board of directors and auditors
12. Resolution on guidelines for appointing the nomination committee
13. Proposal on an authorization for the board of directors to resolve on issuances
14. Closing of the meeting

Proposed resolutions

Item 2 – Election of chairman at the general meeting
The nomination committee proposes that Otto Skolling, or the person proposed by the board of directors if he has an impediment to attend, is elected chairman of the annual general meeting and that Niklas Lindecrantz, or the person proposed by the board of directors if he has an impediment to attend, is elected keeper of the minutes of the annual general meeting.

Item 8 b – Resolution on the dispositions in respect of the company’s profit and loss pursuant to the adopted balance sheet
The board of directors proposes that no dividend shall be distributed for the financial year 2024 and that the company’s result shall be carried forward in the new accounts.

Item 9 – Determination of the number of directors, deputy directors, auditors and deputy auditors
The nomination committee proposes that the board of directors, for the period up to the end of the next annual general meeting, shall be composed of five directors with no deputy directors and that one registered accounting firm is elected as auditor.

Item 10 – Determination of the fees to the board of directors and the auditor
The nomination committee proposes that fees to the board of directors, for the period up to until the end of the next annual general meeting, shall amount to a total of SEK 580,000 with the following distribution: SEK 180,000 to the chairman of the board of directors and SEK 100,000 to each of the other members of the board of directors who are not employed by the company.

The nomination committee proposes that the fee to the auditor, for the period up to the end of the next annual general meeting, shall be paid as incurred on approved accounts.

Item 11 – Election of the board of directors and auditors
The nomination committee proposes re-election of the members of the board of directors Henrik Rammer, Tommy Hedberg, Caroline Lundgren Brandberg, Gunilla Lundmark and Otto Skolling for the period up to until the end of the next annual general meeting.

Furthermore, the nomination committee proposes the re-election of Otto Skolling as chairman of the board of directors for the period up to the end of the next annual general meeting.

Furthermore, the nomination committee proposes re-election of Öhrlings PricewaterhouseCoopers AB as auditor for the period up to the end of the next annual general meeting. Öhrlings PricewaterhouseCoopers AB has announced that the authorized public accountant, Henrik Boman, will be the responsible auditor.

Item 12 – Guidelines for appointing the nomination committee
It is proposed that the annual general meeting resolves that the nomination committee should continue to consist of the four largest shareholders at the time of the notice, namely HAWOC Investment AB, Sifonen, Isak Brandberg AB with closely related persons, and Tommy Hedberg with closely related persons. In the event that a member of the nomination committee resigns, is prevented from performing his/her duties, or if the owner who appointed the member offers their place, the remaining members of the nomination committee shall, if they so decide, among the company's shareholders, appoint a suitable replacement to the nomination committee for the remaining term. In the event that someone acquires shares in the company to such an extent that they become one of the four largest owners of the company, the nomination committee may decide to invite a representative for this shareholder as an additional member of the nomination committee.

The term of the nomination committee shall run until a new nomination committee has been appointed. The company is responsible for costs associated with the performance of the nomination committee's duties. Members of the nomination committee do not receive any remuneration from the company.

The nomination committee's duties shall include evaluating the composition and work of the board of directors and submitting proposals to the annual meeting regarding:

• Chairman of the annual general meeting
• The number and nominations of members of the board of directors to be elected by general meeting
• The chairman of the board of directors
• Remuneration to board members not employed by the company
• If applicable, nomination of auditor and auditor’s fees
• If applicable, guidelines for the appointment of members of the nomination committee and the duties of the nomination committee.

Item 13 – Proposal regarding authorization for the board of directors to resolve on issuances
The board of directors proposes that the general meeting authorizes the board of directors, on one or more occasions, until the next annual general meeting, with or without preferential rights for the shareholders, to resolve upon issue of shares, convertibles and/or warrants. Such new issue resolutions may include provisions of payment in cash and/or payment by way of contribution of non-cash consideration or by set-off of a claim or that subscription shall be subject to other conditions. The terms and conditions for the issue shall be customary to market practice with the possibility to a customary issue discount and shares, warrants and/or convertibles may be issued up to a volume corresponding to in total not more than one-third (1/3) of the shares outstanding in the company at any given time.

The board of directors, or a person appointed by the board of directors, shall be authorized to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.

A valid resolution requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast as well as of all shares represented at the meeting.

Miscellaneous
The board of directors and the CEO shall, if any shareholder so requests and the board of directors considers that it can be done without material harm to the company, provide information on matters that may affect the assessment of an item on the agenda and conditions that may affect the assessment of the company’s financial situation.

Copies of the annual financial report and the auditor’s report will be available at the company’s website, www.chordate.com, no later than two weeks prior to the general meeting. Copies of such documentation will be sent to shareholders who so requests and provides its address.

At the date of this notice, the company has 4,290,764 shares, of which 2,699,620 are ordinary shares and 1,591,144 are preference shares with a total of 2,858,734.4 votes.

For the processing of personal data, please refer to the privacy policy available at the following link: https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf

_____________________
Chordate Medical Holding AB (publ)
the board of directors